KLY.V - Kalytera Therapeutics, Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.0250
0.0000 (0.00%)
As of 2:25PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.0250
Open0.0250
Bid0.0250 x N/A
Ask0.0250 x N/A
Day's Range0.0250 - 0.0250
52 Week Range0.0100 - 0.0600
Volume346,266
Avg. Volume1,391,322
Market Cap12.887M
Beta (5Y Monthly)2.95
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Kalytera Provides Updates Regarding Annual Filings, the Acquisition of Salzman Group, and the Company’s Private Placement

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today provided updates regarding the following three matters: (1) the delay in filing of its annual financial statements for the year ending December 31, 2019 and the accompanying Management’s Discussion and Analysis and related CEO and CFO certifications (collectively, the “Annual Filings”); (2) the acquisition of  Salzman Group, Inc.; and (3) the Company’s previously announced private placement of units. The Company is working with its auditors, Ernst & Young, to complete the Annual Filings. The Company anticipates that final approval and posting of the Annual Filings on www.sedar.com will be completed soon.

  • CNW Group

    IIROC Trading Halt - KLY

    VANCOUVER, BC , June 23, 2020 /CNW/ - The following issues have been halted by IIROC: Company: Kalytera Therapeutics Inc. TSX-Venture Symbol: KLY (All Issues) Reason: CTO Halt Time (ET): 7:45 AM IIROC ...

  • GlobeNewswire

    Kalytera Provides Update Regarding Acquisition of Salzman Group

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") announced today that it is working with Salzman Group toward completing definitive agreements for Kalytera’s acquisition of Salzman Group (the “Acquisition”). On May 19, 2020, Kalytera announced that it had signed a binding Letter of Intent dated May 12, 2020 to acquire Salzman Group, Inc., a privately held company located in West Tisbury, MA (“Salzman Group”).

  • GlobeNewswire

    Kalytera Announces Data Demonstrating that R-107 Prevents Tissue Damage and Increases Survival in a Murine Study of Chlorine Inhalational Lung Injury

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today announced proof-of-concept data demonstrating that R-107 reduces tissue damage and increases survival in a lethal rodent model of chlorine inhalational lung injury (“CILI”) that mimics the pulmonary damage of chlorine exposure in humans. Kalytera announced on May 19, 2020 that it has entered into a binding Letter of Intent to acquire Salzman Group, Inc., a privately held company located in West Tisbury, MA (“Salzman Group”). Salzman Group is the owner of R-107, a proprietary drug with issued and pending composition of matter and method of use patents in approximately 40 countries, including the U.S., Australia, Brazil, China, Europe, India, Japan, Russia, and South Korea.

  • GlobeNewswire

    Kalytera Announces Updates to Its Annual and Interim Filings

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") is providing an update to its news release dated April 28, 2020 on the status of the filing of its annual financial statements for the fiscal year ending December 31, 2019 and the interim financial statements for the interim period ending March 31, 2020, including the accompanying management’s discussion and analysis and related CEO and CFO certifications. On March 18, 2020, the Canadian Securities Administrators issued a notice that as a result of the COVID-19 pandemic the various securities regulators in Canada will be providing coordinated relief consisting of a 45-day extension for certain periodic filings required to be made on or before June 1, 2020.

  • GlobeNewswire

    Kalytera Announces Data from Study in Rats Demonstrating Proof of Concept for R-107 in COVID-19 Associated PAH

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today announced new proof-of-concept data for R-107, its liquid nitric oxide donor, in treatment of pulmonary arterial hypertension (“PAH”) in the setting of acute respiratory distress syndrome (“ARDS”). Professor Salvatore Cuzzocrea, President of the University of Messina and former President of the European Shock Society, carried out the study. Kalytera announced on May 19, 2020 that it has entered into a binding Letter of Intent to acquire Salzman Group, Inc., a privately held company located in West Tisbury, MA (“Salzman Group”).

  • GlobeNewswire

    Kalytera Provides Data Demonstrating that Prodrug R-107 Provides Sustained Release of Nitric Oxide  

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today announced new in vivo data demonstrating that R-107 exhibits rapid conversion to its active payload R-100 in rats, followed by sustained release of nitric oxide from R-100. Kalytera announced on May 19, 2020 that it has entered into a binding Letter of Intent to acquire Salzman Group, Inc., a privately held company located in West Tisbury, MA (“Salzman Group”). Salzman Group is the owner of R-107, a proprietary drug with issued and pending composition of matter and method of use patents in approximately 40 countries, including the U.S., Australia, Brazil, China, Europe, India, Japan, Russia and South Korea.

  • GlobeNewswire

    Kalytera Announces Filing of Provisional Patent Protecting Use of R-107 for Treatment of Coronavirus and COVID-19 Associated Pneumonia

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today announced that Salzman Group, Inc. has filed a provisional patent application protecting the use of its proprietary, liquid, nitric oxide donor, R-107, for therapy of coronavirus and COVID-19 associated pneumonia. If granted, the patent would offer exclusivity to Salzman Group for the use of this agent in the prevention and treatment of coronavirus-associated and COVID-19 lung infections and acute lung injury until 2041, with potentially extended coverage until 2046 in the USA to compensate for clinical development activity as provided by the Hatch-Waxman Act. Salzman Group, Inc., a privately held company located in West Tisbury, MA (“Salzman Group”), signed a binding letter of intent on May 12, 2020 to be acquired by Kalytera.

  • CNW Group

    IIROC Trading Resumption - KLY

    IIROC Trading Resumption - KLY

  • GlobeNewswire

    Kalytera Announces Data Demonstrating that R-107 Preserves Organ Function in a Murine Study Mimicking COVID-19 Lung Disease

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today announced new proof-of-concept data demonstrating that R-107 reduces tissue damage and preserves organ function in a lethal rodent model of sepsis that resembles the circulatory shock seen with COVID-19 associated lung disease. Kalytera announced on May 19, 2020 that it has entered into a binding Letter of Intent to acquire Salzman Group, Inc., a privately held company located in West Tisbury, MA (“Salzman Group”). Salzman Group is the owner of R-107, a proprietary drug with issued and pending composition of matter and method of use patents in approximately 40 countries, including the U.S., Australia, Brazil, China, Europe, India, Japan, Russia and South Korea.

  • GlobeNewswire

    Kalytera Issues CEO Letter to Shareholders

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today issued the following letter to shareholders from the Company’s President and CEO, Robert Farrell. On Tuesday last week, we announced that Kalytera has signed a Letter of Intent to acquire Salzman Group, Inc. (“Salzman Group”). On close of this transaction, Kalytera will have a new pharmaceutical development program, developing R-107 for three indications, including treatment of COVID-19 associated lung disease, chlorine inhalation lung injury (“CILI”) and pulmonary arterial hypertension (“PAH”).

  • GlobeNewswire

    Kalytera Announces Binding Agreement to Acquire Salzman Group

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") announced today that it has signed a binding Letter of Intent dated May 12, 2020 (the “LOI”) to acquire Salzman Group, Inc., a privately held company located in West Tisbury, MA (“Salzman Group”). Salzman Group is the owner of R-107, a proprietary drug with issued and pending composition of matter and method of use patents in approximately 40 countries, including the U.S., Australia, Brazil, China, Europe, India, Japan, Russia and South Korea. Salzman Group is developing R-107 for treatment of COVID-19 associated lung disease, chlorine inhalation lung injury (“CILI”) and pulmonary arterial hypertension (“PAH”).

  • GlobeNewswire

    Kalytera and Stero Biotechs Will Not Proceed with Acquisition

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") has announced that it will not proceed with the previously announced acquisition of Stero Biotechs, Ltd. (“Stero”), and that Stero and Kalytera have terminated the Letter of Intent relating to the acquisition. “Although Kalytera will not proceed with the acquisition of Stero, we are in active discussions with other companies to expand and diversify our operations,” stated Robert Farrell, the Company’s President and CEO. Kalytera Therapeutics, Inc. ("Kalytera") seeks to establish a leading position in the development of novel medicines for a range of important unmet medical needs.

  • GlobeNewswire

    Kalytera Provides Additional Detail Regarding Terms of Stero Biotechs, Ltd. Acquisition

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today provided additional details regarding the terms of its planned acquisition of Stero Biotechs, Ltd. (“Stero”). Stero currently has two ongoing Phase 2a clinical studies evaluating CBD in steroid sparing, and has data from earlier clinical studies demonstrating that co-administration of CBD with steroids may significantly reduce the need for steroid treatment, with the potential to reduce steroid dosing by as much as 80%. As previously disclosed, Kalytera will purchase all shares of Stero for a purchase price of USD $30 million (the “Acquisition Price”), with USD $15 million to be paid in Kalytera common shares at closing; USD $10 million to be paid in Kalytera common shares upon completion of either of Stero's ongoing Phase 2a clinical studies evaluating CBD for steroid sparing in Crohn's disease and in Chronic Urticaria, or upon completion of any other Phase 2 clinical study evaluating CBD for steroid sparing in any other indication; and USD $5 million to be paid in Kalytera common shares upon commencement of any new Phase 2a clinical study evaluating CBD for steroid sparing in any other indication.

  • GlobeNewswire

    Kalytera Announces Extension of Maturity Date of Promissory Note

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") announced today that, in connection with the Company's previously announced intention to acquire Stero Biotechs, Ltd. (“Stero”), the Company and the former shareholders of the Company’s subsidiary, Talent Biotechs Ltd., have agreed to extend the maturity date of the secured promissory note in favor of such shareholders (the “Promissory Note”) to May 15, 2020, the date by which the Company expects to complete the acquisition of Stero.

  • GlobeNewswire

    Kalytera Announces Trading Halt

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") announced today that the securities of the Company have been placed in a trading halt pending review by the TSX Venture Exchange (the “TSXV”) of documents relating to the Company's planned acquisition of Stero Biotechs, Ltd. Kalytera Therapeutics, Inc. ("Kalytera") is pioneering the development of a next generation of cannabinoid therapeutics.

  • GlobeNewswire

    Kalytera to Acquire Stero Biotechs, Ltd.

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") announced today that it has signed a Letter of Intent (“LOI”) to acquire Stero Biotechs, Ltd. (“Stero”). Stero, on the other hand, has issued patents covering the use of CBD for steroid sparing in over 130 different diseases and disorders, which, in the aggregate, represent a multi-billion dollar commercial opportunity.

  • GlobeNewswire

    Kalytera Announces Modification to Sale Period for Shares Issued under Payments Agreement

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced a modification to the sale period contemplated by the irrevocable selling agreement between Salzman Group and its broker with respect to common shares of Kalytera. The shares issued to Salzman Group under the previously announced payments agreement will now be sold by the broker over ten trading days (rather than five trading days). Under the payments agreement with the Salzman Group of Israel, Kalytera paid the Salzman Group USD$300,000 (CDN$399,150) through the issuance of Common Shares of the Company (“Common Shares”) at a deemed issued price of CDN$0.05 per Common Share, for certain services previously provided to the Company by the Salzman Group.

  • GlobeNewswire

    Kalytera Completes Share Issuance under Payments Agreement

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has completed the previously announced transaction under the payments agreement with the Salzman Group of Israel (the “Agreement”), under which Kalytera paid the Salzman Group USD$300,000 (CDN$399,150) through the issuance of Common Shares of the Company (“Common Shares”) at a deemed issued price of CDN$0.05 per Common Share, for certain services previously provided to the Company by the Salzman Group. The corresponding amount owing to Salzman Group has now been satisfied through the issuance of the Common Shares.

  • GlobeNewswire

    Kalytera Announces New Payments Agreement with the Salzman Group of Israel

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has entered into a new agreement reached with the Salzman Group of Israel (the “Agreement”), under which Kalytera will pay the Salzman Group USD$300,000 through issuance of Common Shares of the Company (“Common Shares”) for certain services previously provided to the Company by the Salzman Group. The total amount to be paid to the Salzman Group in Common shares under this new agreement will not exceed USD$300,000.

  • GlobeNewswire

    Kalytera Announces Notice of Allowance of Additional U.S. Patent for Prevention and Treatment of Graft Versus Host Disease

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that the United States Patent and Trademark Office (the “USPTO”) has issued a Notice of Allowance for US Patent Application 15/905/050 covering the use of cannabidiol (“CBD”) in the prevention and treatment of graft versus host disease (“GVHD”). “We are delighted to receive this Notice of Allowance from the USPTO,” said Robert Farrell, Kalytera’s President and CEO. Kalytera has exclusive worldwide rights to the use of CBD in the prevention and treatment of GVHD under two U.S. patents that were issued in 2018, as well as this new U.S. patent and the EU patent that is expected to be granted later this month.

  • GlobeNewswire

    Kalytera Announces Intention to Seek Amendment of Secured Convertible Debentures Due December 2019

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has not paid the principal (in the amount of C$453,000) and interest (in the amount of C$19,323.96) owing on its 9% secured convertible debentures due December 20, 2019 (the “Debentures”). The Company instead intends to seek approval from the TSX Venture Exchange (the “TSXV”) and the holders of outstanding Debentures (collectively, the “Holders”) to extend the maturity date thereof to December 20, 2020 and to reduce the conversion price of the Debentures to C$0.05 per Common Share (from C$0.13 per Common Share). There is no assurance that the amendments requested by the Company will be approved by the TSXV or the Holders.

  • GlobeNewswire

    Kalytera Reports Third Quarter 2019 Financial Results

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today reported financial results for the third quarter of 2019. In Q3 2019, the Company had no revenues from product sales, and recorded a net loss of approximately $1.0 million ($0.002 per Common Share), compared with a net profit of approximately $1.8 million ($0.01 per Common Share) in Q3, 2018. The Company’s net loss in Q3 2019 and net profit in Q3 2018 resulted from several factors in each such period, including, primarily, changes in the amounts of certain contingent liabilities and in-process research and development that were charged to income.

  • GlobeNewswire

    Published Studies Provide Further Support For Kalytera’s Program Evaluating CBD in GVHD

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that research reported in two peer-reviewed articles published in Blood provide further evidence supporting the activity of cannabidiol (“CBD”) in prevention and treatment of acute graft versus host disease (“GVHD”) and associated comorbidities. Blood is a peer-reviewed medical journal published by the American Society of Hematology. Acute GVHD is a life-threatening complication commonly occurring after bone marrow transplant procedures.

  • GlobeNewswire

    Kalytera Announces Closing of Final Tranche of Private Placement of Common Shares and Common Share Purchase Warrants and Amendments to Secured Convertible Debenture Units

    Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera”) is pleased to announce that it has closed an additional and final tranche of its private placement, for 2,811,111 common shares of the Company and 2,811,111 common share purchase warrants for aggregate gross proceeds of approximately C$126,500. Industrial Alliance Securities Inc. will receive compensation in connection with this tranche of the private placement consisting of a cash commission equal to C$10,120 and will be issued 224,889 warrants bearing the same terms as those issued in the offering. All securities issued in this tranche are subject to a hold period expiring on February 26, 2020 in accordance with applicable securities laws.